## For Immediate Release

Company name: DAIICHI SANKYO COMPANY, LIMITED

Representative: Takashi Shoda, President and Representative Director (Code no.: 4568, First Section, Tokyo, Osaka and Nagoya Stock Exchanges)

Please address inquiries to Toshio Takahashi, Corporate Officer in Charge,

Corporate Communications Department

Telephone: +81-3-6225-1126 http://www.daiichisankyo.co.jp/

## The transfer of all commercial rights for Panaldine®

Tokyo, April 2, 2007 — DAIICHI SANKYO COMPANY, LIMITED and Sanofi-aventis announced today the transfer of all commercial rights for Panaldine<sup>®</sup> (ticlopidine hydrochloride) in Japan from DAIICHI SANKYO to Sanofi-aventis. The transfer will be implemented in conformity with local regulatory requirements and such transfer is expected to occur on October 1, 2007. Given their long-standing relationship, both parties agreed to collaborate in the future in the areas of manufacturing and distribution in Japan.